Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Department of Justice
Express Scripts
Fish and Richardson
McKesson
Federal Trade Commission
US Army
QuintilesIMS
Queensland Health

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Buprenorphine Hydrochloride And Naloxone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000243 Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone Terminated National Institute on Drug Abuse (NIDA) N/A Buprenorphine is a drug that may be helpful in treating opioid dependent individuals who were previously maintained on methadone. The purpose of this study is to determine the effects of different doses of buprenorphine/naloxone in treating opioid dependent individuals who were previously maintained on methadone.
NCT00000298 Buprenorphine Combination Tablet Feasibility - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence."
NCT00000326 Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Buprenorphine Hydrochloride And Naloxone Hydrochloride

Condition Name

Condition Name for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Intervention Trials
Opioid-Related Disorders 28
Opioid Dependence 15
Heroin Dependence 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Intervention Trials
Opioid-Related Disorders 44
Heroin Dependence 15
Substance-Related Disorders 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Buprenorphine Hydrochloride And Naloxone Hydrochloride

Trials by Country

Trials by Country for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Location Trials
United States 177
Norway 5
Canada 4
Taiwan 3
Finland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Location Trials
New York 20
California 18
Maryland 16
Florida 11
Utah 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Buprenorphine Hydrochloride And Naloxone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Clinical Trial Phase Trials
Completed 59
Terminated 9
Recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Buprenorphine Hydrochloride And Naloxone Hydrochloride

Sponsor Name

Sponsor Name for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 35
Indivior Inc. 12
University of Colorado, Denver 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Buprenorphine Hydrochloride And Naloxone Hydrochloride
Sponsor Trials
Other 76
NIH 37
Industry 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Colorcon
McKesson
McKinsey
Federal Trade Commission
Queensland Health
Fish and Richardson
Chinese Patent Office
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.